During the past decades, encouraging progress has been made in the prevention of surgical site infections (SSI). However, as SSI still occur today, strategic prevention measures such as standardized skin antisepsis must be implemented and rigorously promoted. Recent discoveries in skin physiology necessitate the development of novel antiseptic agents and procedures in order to ameliorate their efficacy. In particular, alternate target structures in the skin need to be taken into consideration for the development of the next generation of antiseptics. Recent investigations have shown that a high number of microorganisms are located within and in the close vicinity of the hair follicles. This suggests that these structures are an important reservoir of bacterial growth and activity in human skin. To date, it has not been fully elucidated to what extent conventional liquid antiseptics sufficiently target the hair follicle-related microbial population. Modern technologies such as tissue-tolerable plasma (TTP) have been tested for their potential antiseptic efficiency by reducing the bacterial load in the skin and in the hair follicles. First experiments using liposomes to deliver antiseptics into the hair follicles have been evaluated for their potential clinical application. The present review evaluates these two innovative methods for their efficacy and applicability in preoperative skin antiseptics.

Keywords:
Surgical site infections, Skin antisepsis, Tissue-tolerable plasma, Nanoparticles, Liposomes
1.
Rosenthal R, Weber W, Marti W, Misteli H, Reck S, Dangel M, Oertli D, Widmer A: Surveillance of surgical site infections by surgeons: biased underreporting or useful epidemiological data? J Hosp Infect 2010;75:178-182.
2.
Kramer A, Kampf G, Oldhafer K, et al: Prävention von SSI in der Chirurgie; in Kramer A, Assadian O, Exner M, et al. (eds): Krankenhaus- und Praxishygiene. München, Elsevier Urban & Fischer, 2011.
3.
Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ: The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999;20:725-730.
4.
Dissemond J, Assadian O, Gerber V, Kingsley A, Kramer A, Leaper D, Mosti G, Piatkowski de Grzymala A, Riepe G, Risse A: Classification of wounds at risk and their antimicrobial treatment with polihexanide: a practice-oriented expert recommendation. Skin Pharmacol Physiol 2011;24:245-255.
5.
Dettenkofer M, Wilson C, Gratwohl A, Schmoor C, Bertz H, Frei R, Heim D, Luft D, Schulz S, Widmer A: Skin disinfection with octenidine dihydrochloride for central venous catheter site care: a double-blind, randomized, controlled trial. Clin Microbiol Infect 2010;16:600-606.
6.
Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, Miller HJ, Awad SS, Crosby CT, Mosier MC: Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362:18-26.
7.
Levin I, Amer-Alshiek J, Avni A, Lessing JB, Satel A, Almog B: Chlorhexidine and alcohol versus povidone-iodine for antisepsis in gynecological surgery. J Womens Health 2011;20:321-324.
8.
Swenson BR, Hedrick TL, Metzger R, Bonatti H, Pruett TL, Sawyer RG: Effects of preoperative skin preparation on postoperative wound infection rates: a prospective study of 3 skin preparation protocols. Infect Control Hosp Epidemiol 2009;30:964.
9.
Dumville JC, McFarlane E, Edwards P, Lipp A, Holmes A: Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev 2013;3:CD003949.
10.
Gebel J, Werner HP, Kirsch-Altena A, Bansemir K: Standardmethoden der DGHM zur Prüfung chemischer Desinfektionsverfahren. Wiesbaden, mhp, 2001.
11.
Hübner NO, Kellner N, Partecke L, Koburger T, Heidecke CD, Kohlmann T, Kramer A: Determination of antiseptic efficacy of rubs on the forearm and consequences for surgical hand disinfection. J Hosp Infect 2011;78:11-15.
12.
Hübner NO, Assadian O, Grohmann S, Diab-Elschahawi M, Kramer A: Efficacy of five alcohol-based skin antiseptics on sebaceous skin used at shorter application times than the current recommendation of 10 min. Eur J Clin Microbiol Infect Dis 2011;30:825-829.
13.
Daeschlein G NM, Bluhm J, Krueger C, von Podewils S, Gümbel D, Hinz P, Haase H, Dohmen PM, Assadian O, Koburger T, Kramer A: Effect of pre-operative skin sealing with cyanoacrylate on microbial contamination of surgical wounds following trauma surgery: a prospective, blinded, controlled, randomized clinical trial. Int J Infect Dis, submitted.
14.
Heinlin J, Isbary G, Stolz W, Zeman F, Landthaler M, Morfill G, Shimizu T, Zimmermann J, Karrer S: A randomized two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus. J Eur Acad Dermatol Venereol 2013;27:324-331.
15.
Dohmen PM, Gabbieri D, Weymann A, Linneweber J, Geyer T, Konertz W: A retrospective non-randomized study on the impact of InteguSeal, a preoperative microbial skin sealant, on the rate of surgical site infections after cardiac surgery. Int J Infect Dis 2011;15:e395-e400.
16.
von Eckardstein AS, Lim CH, Dohmen PM, Pêgo-Fernandes PM, Cooper WA, Oslund SG, Kelley EL: A randomized trial of a skin sealant to reduce the risk of incision contamination in cardiac surgery. Ann Thorac Surg 2011;92:632-637.
17.
Dohmen P, Gabbieri D, Weymann A, Linneweber J, Konertz W: Reduction in surgical site infection in patients treated with microbial sealant prior to coronary artery bypass graft surgery: a case-control study. J Hosp Infect 2009;72:119.
18.
Waldow T, Szlapka M, Hensel J, Plötze K, Matschke K, Jatzwauk L: Skin sealant InteguSeal® has no impact on prevention of postoperative mediastinitis after cardiac surgery. J Hosp Infect 2012;81:278-282.
19.
Parks PJ, Babadjanian C, Johnson EJ, Walters SA: Infection reduction with antimicrobial-impregnated incise foils (poster). Eur Bone Joint Infect Soc 26th Ann Meet, Corfu, 2007.
20.
CSN EN 12791: Chemical disinfectants and antiseptics - surgical hand disinfection - test method and requirements (phase 2/step 2). 2005.
21.
Kramer A, Hübner N, Below H, Heidecke CD, Assadian O: Improving adherence to surgical hand preparation. J Hosp Infect 2008;70:35-43.
22.
Kramer A, Below H, Bieber N, Kampf G, Toma CD, Huebner NO, Assadian O: Quantity of ethanol absorption after excessive hand disinfection using three commercially available hand rubs is minimal and below toxic levels for humans. BMC Infect Dis 2007;7:117.
23.
Below H, Partecke I, Huebner NO, Bieber N, Nicolai T, Usche A, Assadian O, Below E, Kampf G, Parzefall W: Dermal and pulmonary absorption of propan-1-ol and propan-2-ol from hand rubs. Am J Infect Control 2012;40:250-257.
24.
Koburger T, Pitts D, Kramer A: Results of a field study on the influence of HygienicWood mattress toppers on the number of mites in bed dust and the state of health of people with house dust mite allergies. GMS Krankenhhyg Interdiszip 2010 Sep 21; 5 (2). pii:Doc04. DOI:10.3205/dgkh000147.
25.
Ulmer M, Patzelt A, Vergou T, Lademann J, Richter H, Kramer A, Müller G, Sterry W, Lange-Asschenfeldt B: In vitro investigation of the follicular penetration of porcine ear skin using a nanoparticle-emulsion containing the antiseptic polihexanide. Laser Phys Lett 2012;9:381.
26.
Ulmer M, Patzelt A, Vergou T, Richter H, Müller G, Kramer A, Sterry W, Czaika V, Lademann J: In vivo investigation of the efficiency of a nanoparticle-emulsion containing polihexanide on the human skin. Eur J Pharm Biopharm 2013;84:325-329.
27.
Lange-Asschenfeldt B, Marenbach D, Lang C, Patzelt A, Ulrich M, Maltusch A, Terhorst D, Stockfleth E, Sterry W, Lademann J: Distribution of bacteria in the epidermal layers and hair follicles of the human skin. Skin Pharmacol Physiol 2011;24:305-311.
28.
Otberg N, Richter H, Knuttel A, Schaefer H, Sterry W, Lademann J: Laser spectroscopic methods for the characterization of open and closed follicles. Laser Phys Lett 2004;1:46-49.
29.
Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J: Variations of hair follicle size and distribution in different body sites. J Invest Dermatol 2004;122:14-19.
30.
von Woedtke T, Kramer A, Weltmann KD: Plasma sterilization: what are the conditions to meet this claim? Plasma Processes Polym 2008;5:534-539.
31.
Hauser J, Halfmann H, Awakowicz P, Köller M, Esenwein S: A double inductively coupled low-pressure plasma for sterilization of medical implant materials (in German). Biomed Tech (Berl) 2008;53:199-203.
32.
Kim B, Yun H, Jung S, Jung Y, Jung H, Choe W, Jo C: Effect of atmospheric pressure plasma on inactivation of pathogens inoculated onto bacon using two different gas compositions. Food Microbiol 2011;28:9-13.
33.
Moreau M, Orange N, Feuilloley M: Non-thermal plasma technologies: new tools for bio-decontamination. Biotechnol Adv 2008;26:610-617.
34.
Morfill G, Shimizu T, Steffes B, Schmidt H: Nosocomial infections: a new approach towards preventive medicine using plasmas. New J Phys 2009;11:115019.
35.
Nosenko V, Zhdanov S, Ivlev A, Knapek C, Morfill G: 2D melting of plasma crystals: equilibrium and nonequilibrium regimes. Phys Rev Lett 2009;103:015001.
36.
Kramer A, Lademann J, Bender C, Sckell A, Hartmann B, Münch S, Hinz P, Ekkernkamp A, Matthes R, Koban I, et al: Suitability of tissue tolerable plasmas (TTP) for the management of chronic wounds. Clin Plasma Med 2013;1:11-18.
37.
Hübner NO, Matthes R, Koban I, Rändler C, Müller G, Bender C, Kindel E, Kocher T, Kramer A: Efficacy of chlorhexidine, polihexanide and tissue-tolerable plasma against Pseudomonas aeruginosa biofilms grown on polystyrene and silicone materials. Skin Pharmacol Physiol 2010;23:28-34.
38.
Koban I, Matthes R, Hübner NO, Welk A, Meisel P, Holtfreter B, Sietmann R, Kindel E, Weltmann KD, Kramer A: Treatment of Candida albicans biofilms with low-temperature plasma induced by dielectric barrier discharge and atmospheric pressure plasma jet. New J Phys 2010;12:073039.
39.
Koban I, Holtfreter B, Hübner NO, Matthes R, Sietmann R, Kindel E, Weltmann KD, Welk A, Kramer A, Kocher T: Antimicrobial efficacy of non-thermal plasma in comparison to chlorhexidine against dental biofilms on titanium discs in vitro: proof of principle experiment. J Clin Periodontol 2011;38:956-965.
40.
Shimizu T, Steffes B, Pompl R, Jamitzky F, Bunk W, Ramrath K, Georgi M, Stolz W, Schmidt HU, Urayama T: Characterization of microwave plasma torch for decontamination. Plasma Processes Polym 2008;5:577-582.
41.
Czaika V, Alborova A, Richter H, Sterry W, Vergou T, Antoniou C, Lademann J, Koch S: Comparison of transepidermal water loss and laser scanning microscopy measurements to assess their value in the characterization of cutaneous barrier defects. Skin Pharmacol Physiol 2012;25:39-46.
42.
Lademann O, Kramer A, Richter H, Patzelt A, Meinke M, Roewert-Huber J, Czaika V, Weltmann K, Hartmann B, Koch S: Antisepsis of the follicular reservoir by treatment with tissue-tolerable plasma (TTP). Laser Phys Lett 2011;8:313.
43.
Fluhr JW, Sassning S, Lademann O, Darvin ME, Schanzer S, Kramer A, Richter H, Sterry W, Lademann J: In vivo skin treatment with tissue-tolerable plasma influences skin physiology and antioxidant profile in human stratum corneum. Exp Dermatol 2012;21:130-134.
44.
Partecke LI, Evert K, Haugk J, Doering F, Normann L, Diedrich S, Weiss FU, Evert M, Huebner NO, Guenther C, et al: Tissue tolerable plasma (TTP) induces apoptosis in pancreatic cancer cells in vitro and in vivo. BMC Cancer 2012;12:473.
45.
Heise R, Skazik C, Marquardt Y, Czaja K, Sebastian K, Kurschat P, Gan L, Denecke B, Ekanayake-Bohlig S, Wilhelm KP, Merk HF, Baron JM: Dexpanthenol modulates gene expression in skin wound healing in vivo. Skin Pharmacol Physiol 2012;25:241-248.
46.
Hammann A, Huebner NO, Bender C, Ekkernkamp A, Hartmann B, Hinz P, Kindel E, Koban I, Koch S, Kohlmann T: Antiseptic efficacy and tolerance of tissue-tolerable plasma compared with two wound antiseptics on artificially bacterially contaminated eyes from commercially slaughtered pigs. Skin Pharmacol Physiol 2010;23:328-332.
47.
Daeschlein G, Scholz S, von Woedtke T, Niggemeier M, Kindel E, Brandenburg R, Weltmann KD, Junger M: In vitro killing of clinical fungal strains by low-temperature atmospheric-pressure plasma jet. IEEE Trans Plasma Sci 2011;39:815-821.
48.
Daeschlein G, von Woedtke T, Kindel E, Brandenburg R, Weltmann KD, Jünger M: Antibacterial activity of an atmospheric pressure plasma jet against relevant wound pathogens in vitro on a simulated wound environment. Plasma Processes Polym 2010;7:224-230.
49.
Lademann O, Kramer A, Richter H, Patzelt A, Meinke M, Czaika V, Weltmann KD, Hartmann B, Koch S: Skin disinfection by plasma-tissue interaction: comparison of the effectivity of tissue-tolerable plasma and a standard antiseptic. Skin Pharmacol Physiol 2011;24:284-288.
50.
Isbary G, Heinlin J, Shimizu T, Zimmermann J, Morfill G, Schmidt HU, Monetti R, Steffes B, Bunk W, Li Y: Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial. Br J Dermatol 2012;167:404-410.
51.
Bender CP, Hübner NO, Weltmann KD, Scharf C, Kramer A: Tissue tolerable plasma and polihexanide: are synergistic effects possible to promote healing of chronic wounds? In vivo and in vitro results; in Machala Z, Hensel K, Akishev Y (eds): Plasma for Bio-Decontamination, Medicine and Food Security. Dordrecht, Springer, 2012, pp 321-334.
52.
Weltmann K, Kindel E, Brandenburg R, Meyer C, Bussiahn R, Wilje C, von Woedtke T: Atmospheric pressure plasma jet for medical therapy: plasma parameters and risk estimation. Contrib Plasma Phys 2009;49:631-640.
53.
Matthes R, Bender C, Hübner NO, Müller G, Kohl K, Mentz J, Koban I, Kindel E, Kocher T, Weltmann KD: Influencing of the penetration of Pseudomonas aeruginosa into a 3-D epidermis model and the inactivation with tissue tolerable plasma. GMS Krankenhhyg Interdiszip 2009;4:Doc8.
54.
Lademann O, Richter H, Meinke MC, Patzelt A, Kramer A, Hinz P, Weltmann KD, Hartmann B, Koch S: Drug delivery through the skin barrier enhanced by treatment with tissue-tolerable plasma. Exp Dermatol 2011;20:488-490.
55.
Lademann O, Richter H, Kramer A, Patzelt A, Meinke M, Graf C, Gao Q, Korotianskiy E, Rühl E, Weltmann KD: Stimulation of the penetration of particles into the skin by plasma tissue interaction. Laser Phys Lett 2011;8:758-764.
56.
Lademann J, Richter H, Alborova A, Humme D, Patzelt A, Kramer A, Weltmann KD, Hartmann B, Ottomann C, Fluhr JW: Risk assessment of the application of a plasma jet in dermatology. J Biomed Opt 2009;14:054025.
57.
Lademann O, Richter H, Patzelt A, Alborova A, Humme D, Weltmann KD, Hartmann B, Hinz P, Kramer A, Koch S: Application of a plasma-jet for skin antisepsis: analysis of the thermal action of the plasma by laser scanning microscopy. Laser Phys Lett 2010;7:458-462.
58.
Trauer S, Lademann J, Knorr F, Richter H, Liebsch M, Rozycki C, Balizs G, Buttemeyer R, Linscheid M, Patzelt A: Development of an in vitro modified skin absorption test for the investigation of the follicular penetration pathway of caffeine. Skin Pharmacol Physiol 2010;23:320-327.
59.
Patzelt A, Knorr F, Blume-Peytavi U, Sterry W, Lademann J: Hair follicles, their disorders and their opportunities. Drug Discov Today Dis Mech 2008;5:e173-e181.
60.
Lademann J, Knorr F, Richter H, Blume-Peytavi U, Vogt A, Antoniou C, Sterry W, Patzelt A: Hair follicles: an efficient storage and penetration pathway for topically applied substances. Skin Pharmacol Physiol 2008;21:150-155.
61.
Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J: Nanoparticles: an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 2007;66:159-164.
62.
Meinke M, Patzelt A, Richter H, Schanzer S, Sterry W, Filbry A, Bohnsack K, Rippke F, Galecka J, Fölster-Holst R: Prevention of follicular penetration: barrier-enhancing formulations against the penetration of pollen allergens into hair follicles. Skin Pharmacol Physiol 2010;24:144-150.
63.
Gharib A, Faezizadeh Z, Godarzee M: Therapeutic efficacy of epigallocatechin gallate-loaded nanoliposomes against burn wound infection by methicillin-resistant Staphylococcus aureus. Skin Pharmacol Physiol 2013;26:68-75.
64.
Mohanraj V, Chen Y: Nanoparticles: a review. Trop J Pharm Res 2006;5:561-573.
65.
Nohynek G, Dufour E, Roberts M: Nanotechnology, cosmetics and the skin: is there a health risk? Skin Pharmacol Physiol 2008;21:136-149.
66.
Medina C, Santos Martinez M, Radomski A, Corrigan O, Radomski M: Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007;150:552-558.
67.
Davis ME: Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-782.
68.
Nakamizo S, Egawa G, Doi H, Natsuaki Y, Miyachi Y, Kabashima K: Topical treatment with basic fibroblast growth factor promotes wound healing and barrier recovery induced by skin abrasion. Skin Pharmacol Physiol 2013;26:22-29.
69.
Wigger-Alberti W, Stauss-Grabo M, Grigo K, Atiye S, Williams R, Korting HC: Efficacy of a tyrothricin-containing wound gel in an abrasive wound model for superficial wounds. Skin Pharmacol Physiol 2013;26:52-56.
70.
Lademann J, Richter H, Schanzer S, Knorr F, Meinke M, Sterry W, Patzelt A: Penetration and storage of particles in human skin: perspectives and safety aspects. Eur J Pharm Biopharm 2011;77:465-468.
71.
Schafer-Korting M, Holtje M, Korting HC, Holtje HD: Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration. Skin Pharmacol Physiol 2010;23:6-14.
72.
Siqueira NM, Contri RV, Paese K, Beck RC, Pohlmann AR, Guterres SS: Innovative sunscreen formulation based on benzophenone-3-loaded chitosan-coated polymeric nanocapsules. Skin Pharmacol Physiol 2011;24:166-174.
73.
Wu X, Landfester K, Musyanovych A, Guy RH: Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol Physiol 2010;23:117-123.
74.
Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U: Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol 2003;123:168-176.
75.
Jung S, Patzelt A, Otberg N, Thiede G, Sterry W, Lademann J: Strategy of topical vaccination with nanoparticles. J Biomed Opt 2009;14:021001.
76.
Müller G, Kramer A, Schmitt J, Harden D, Koburger T: Reduced cytotoxicity of polyhexamethylene biguanide hydrochloride (PHMB) by egg phosphatidylcholine while maintaining antimicrobial efficacy. Chem Biol Interact 2011;190:171-178.
77.
Benita S, Levy M: Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J Pharm Sci 1993;82:1069-1079.
78.
Hofheinz R, Gnad-Vogt S, Beyer U, Hochhaus A: Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005;16:691-707.
79.
Fang J, Hwang T, Huang Y: Liposomes as vehicles for enhancing drug delivery via skin routes. Curr Nanosci 2006;2:55-70.
80.
Kim H, Kim J, Park J, Kim SH, Uchida Y, Holleran WM, Cho Y: Water extract of gromwell (Lithospermum erythrorhizon) enhances migration of human keratinocytes and dermal fibroblasts with increased lipid synthesis in an in vitro wound scratch model. Skin Pharmacol Physiol 2012;25:57-64.
81.
Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda A: Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J Control Release 2005;103:123-136.
82.
Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J: Variations of hair follicle size and distribution in different body sites. J Invest Dermatol 2004;122:14-19.
83.
Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J, Schaefer U, Lehr C, Wepf R, Sterry W: Nanoparticles: an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 2007;66:159-164.
84.
Hubner NO, Matthes R, Koban I, Randler C, Muller G, Bender C, Kindel E, Kocher T, Kramer A: Efficacy of chlorhexidine, polihexanide and tissue-tolerable plasma against Pseudomonas aeruginosa biofilms grown on polystyrene and silicone materials. Skin Pharmacol Physiol 2010;23(suppl):28-34.
85.
Eberlein T, Assadian O: Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination. Skin Pharmacol Physiol 2010;23:45-51.
86.
Kramer A, Hubner N, Assadian O, Mulder G: Polihexanide: perspectives on clinical wound antisepsis. Skin Pharmacol Physiol 2010;23:1-3.
87.
Brogden NK, Mehalick L, Fischer CL, Wertz PW, Brogden KA: The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacol Physiol 2012;25:167-181.
88.
Daeschlein G, Alborova J, Patzelt A, Kramer A, Lademann J: Kinetics of physiological skin flora in a suction blister wound model on healthy subjects after treatment with water-filtered infrared-A radiation. Skin Pharmacol Physiol 2012;25:73-77.
89.
Roth C, Beule A, Kramer A, Hosemann W, Kohlmann T, Scharf C: Response analysis of stimulating efficacy of polihexanide in an in vitro wound model with respiratory ciliary epithelial cells. Skin Pharmacol Physiol 2010;23:35-40.
90.
Lademann J, Richter H, Schanzer S, Patzelt A, Thiede G, Kramer A, Weltmann KD, Hartmann B, Lange-Asschenfeldt B: Comparison of the antiseptic efficacy of tissue-tolerable plasma and an octenidine hydrochloride-based wound antiseptic on human skin. Skin Pharmacol Physiol 2012;25:100-106.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.